Literature DB >> 18647941

Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin.

Steven R Barthel1, Jacyln D Gavino, Georg K Wiese, Jennifer M Jaynes, Javed Siddiqui, Charles J Dimitroff.   

Abstract

Prostate cancer (PCa) cell tethering and rolling on microvascular endothelium has been proposed to promote the extravasation of PCa cells. We have shown that these adhesive events are mediated through binding interactions between endothelial (E)-selectin and Lewis carbohydrates on PCa cells. Prior data indicate that E-selectin-mediated rolling of bone-metastatic PCa MDA PCa 2b (MDA) cells is dependent on sialyl Lewis X (sLe(X))-bearing glycoproteins. To explore the molecular basis of sLe(X) synthesis and E-selectin ligand (ESL) activity on PCa cells, we compared and contrasted the expression level of glycosyltransferases, characteristically involved in sLe(X) and ESL synthesis, in ESL(+) MDA cells among other ESL(-) metastatic PCa cell lines. We also created and examined ESL(hi) and ESL(lo) variants of MDA cells to provide a direct comparison of the glycosyltransferase expression level. We found that normal prostate tissue and all metastatic PCa cell lines expressed glycosyltransferases required for sialo-lactosamine synthesis, including N-acetylglucosaminyl-, galactosyl-, and sialyltransferases. However, compared with expression in normal prostate tissue, ESL(+) MDA cells expressed a 31- and 10-fold higher level of alpha1,3 fucosyltransferases (FT) 3 and 6, respectively. Moreover, FT3 and FT6 were expressed at 2- to 354-fold lower levels in ESL(-) PCa cell lines. Consistent with these findings, ESL(hi) MDA cells expressed a 131- and 51-fold higher level of FT3 and FT6, respectively, compared with expression in ESL(lo) MDA cells. We also noted that alpha1,3 FT7 was expressed at a 5-fold greater level in ESL(hi) MDA cells. Furthermore, ESL(lo) MDA cells did not display sLe(X) on glycoproteins capable of bearing sLe(X), notably P-selectin glycoprotein ligand-1. These results implicate the importance of alpha1,3 FT3, FT6, and/or FT7 in sLe(X) and ESL synthesis on metastatic PCa cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18647941      PMCID: PMC2574550          DOI: 10.1093/glycob/cwn070

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  84 in total

1.  beta4GalT-II is a key regulator of glycosylation of the proteins involved in neuronal development.

Authors:  Norihiko Sasaki; Hiroshi Manya; Reiko Okubo; Kazuhiro Kobayashi; Hideki Ishida; Tatsushi Toda; Tamao Endo; Shoko Nishihara
Journal:  Biochem Biophys Res Commun       Date:  2005-07-22       Impact factor: 3.575

2.  Alpha1,3-L-fucosyltransferase expression in developing human myeloid cells. Antigenic, enzymatic, and mRNA analyses.

Authors:  J L Clarke; W Watkins
Journal:  J Biol Chem       Date:  1996-04-26       Impact factor: 5.157

3.  Peritoneal colonization by human pancreatic cancer cells is inhibited by antisense FUT3 sequence.

Authors:  M Aubert; L Panicot-Dubois; C Crotte; V Sbarra; D Lombardo; M O Sadoulet; E Mas
Journal:  Int J Cancer       Date:  2000-11-15       Impact factor: 7.396

Review 4.  Glycosylation in the control of selectin counter-receptor structure and function.

Authors:  John B Lowe
Journal:  Immunol Rev       Date:  2002-08       Impact factor: 12.988

5.  Rolling of human bone-metastatic prostate tumor cells on human bone marrow endothelium under shear flow is mediated by E-selectin.

Authors:  Charles J Dimitroff; Mirna Lechpammer; Denise Long-Woodward; Jeffery L Kutok
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

6.  CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion.

Authors:  Shailesh Singh; Udai P Singh; William E Grizzle; James W Lillard
Journal:  Lab Invest       Date:  2004-12       Impact factor: 5.662

7.  Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo.

Authors:  Yan-Xi Sun; Jingcheng Wang; Charles E Shelburne; Dennis E Lopatin; Arul M Chinnaiyan; Mark A Rubin; Kenneth J Pienta; Russell S Taichman
Journal:  J Cell Biochem       Date:  2003-06-01       Impact factor: 4.429

Review 8.  Transcriptional regulation of expression of carbohydrate ligands for cell adhesion molecules in the selectin family.

Authors:  R Kannagi
Journal:  Adv Exp Med Biol       Date:  2001       Impact factor: 2.622

9.  Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases.

Authors:  Jeffrey A Nemeth; Michael L Cher; Zhao Zhou; Chadwick Mullins; Sunita Bhagat; Mohit Trikha
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

10.  CD44 is a major E-selectin ligand on human hematopoietic progenitor cells.

Authors:  C J Dimitroff; J Y Lee; S Rafii; R C Fuhlbrigge; R Sackstein
Journal:  J Cell Biol       Date:  2001-06-11       Impact factor: 10.539

View more
  28 in total

Review 1.  Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?

Authors:  Nayoung Lee; Steven R Barthel; Tobias Schatton
Journal:  Lab Invest       Date:  2013-10-14       Impact factor: 5.662

2.  CD44 variant isoforms expressed by breast cancer cells are functional E-selectin ligands under flow conditions.

Authors:  Venktesh S Shirure; Tiantian Liu; Luis F Delgadillo; Chaz M Cuckler; David F J Tees; Fabian Benencia; Douglas J Goetz; Monica M Burdick
Journal:  Am J Physiol Cell Physiol       Date:  2014-10-22       Impact factor: 4.249

Review 3.  Metabolic oligosaccharide engineering: implications for selectin-mediated adhesion and leukocyte extravasation.

Authors:  Ruben T Almaraz; Mohit P Mathew; Elaine Tan; Kevin J Yarema
Journal:  Ann Biomed Eng       Date:  2011-10-30       Impact factor: 3.934

4.  Definition of molecular determinants of prostate cancer cell bone extravasation.

Authors:  Steven R Barthel; Danielle L Hays; Erika M Yazawa; Matthew Opperman; Kempland C Walley; Leonardo Nimrichter; Monica M Burdick; Bryan M Gillard; Michael T Moser; Klaus Pantel; Barbara A Foster; Kenneth J Pienta; Charles J Dimitroff
Journal:  Cancer Res       Date:  2012-11-13       Impact factor: 12.701

5.  Knockdown of fucosyltransferase III disrupts the adhesion of circulating cancer cells to E-selectin without affecting hematopoietic cell adhesion.

Authors:  Xiaoyan Yin; Kuldeepsinh Rana; Varun Ponmudi; Michael R King
Journal:  Carbohydr Res       Date:  2010-07-21       Impact factor: 2.104

6.  Metabolic inhibition of sialyl-Lewis X biosynthesis by 5-thiofucose remodels the cell surface and impairs selectin-mediated cell adhesion.

Authors:  Wesley F Zandberg; Jayakanthan Kumarasamy; B Mario Pinto; David J Vocadlo
Journal:  J Biol Chem       Date:  2012-09-27       Impact factor: 5.157

7.  Glycosylation potential of human prostate cancer cell lines.

Authors:  Yin Gao; Vishwanath B Chachadi; Pi-Wan Cheng; Inka Brockhausen
Journal:  Glycoconj J       Date:  2012-07-28       Impact factor: 2.916

8.  Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking.

Authors:  Steven R Barthel; Georg K Wiese; Jaehyung Cho; Matthew J Opperman; Danielle L Hays; Javed Siddiqui; Kenneth J Pienta; Bruce Furie; Charles J Dimitroff
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-04       Impact factor: 11.205

Review 9.  Leveraging fluorinated glucosamine action to boost antitumor immunity.

Authors:  Charles J Dimitroff
Journal:  Curr Opin Immunol       Date:  2012-12-06       Impact factor: 7.486

10.  Increased bisecting N-acetylglucosamine and decreased branched chain glycans of N-linked glycoproteins in expressed prostatic secretions associated with prostate cancer progression.

Authors:  Julius O Nyalwidhe; Lucy R Betesh; Thomas W Powers; E Ellen Jones; Krista Y White; Tanya C Burch; Jasmin Brooks; Megan T Watson; Raymond S Lance; Dean A Troyer; O John Semmes; Anand Mehta; Richard R Drake
Journal:  Proteomics Clin Appl       Date:  2013-09-13       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.